Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTThe altered metabolism of cancer cells is important for their viability, growth and proliferation, and targeting such metabolic alterations is a validated strategy for ablating tumor cells while sparing normal tissue. However, little is known about the metabolic requirements underlying cancer cell aggressiveness -a phenotype that includes increased drug resistance, invasiveness, stem-like properties, and metastatic potential, and is often characterized by an epithelial-to-mesenchymal transition (EMT) in cellular identity. Triple-negative and metastatic breast cancers are particularly aggressive, lack effective therapies, and therefore carry a poor survival prognosis. To identify targetable metabolic requirements of these cancers, we developed a complete metabolomic profiling platform including optimized methods for sample preparation, liquid chromatography/mass spectrometry (LC/MS), and untargeted data analysis. Furthermore, using a cell-culture model, we identified the metabolic enzyme dihydropyrimidine dehydrogenase (DPYD) as specifically required for the EMT. These results showcase the capability of our LC/MS-based metabolomics platform to measure small molecules in the context of cancer metabolism; in addition, we identify DPYD as the first metabolic enzyme specifically required for the EMT, a process associated with the acquisition of aggressive characteristics in breast cancer and other carcinomas. This work led to a manuscript (Appendix 2) now under revision for publication in Cell.
SUBJECT TERMSbreast cancer, carcinoma, aggressiveness, metastasis, epithelial-to-mesenchymal transition, metabolism, pyrimidine, stem-like